Women exposed to the chemical triclosan, which is found in products like soap and toothpaste, are at an increased risk for developing osteoporosis.
Women exposed to the chemical triclosan (TCS), which is found in products like soap and toothpaste, are at an increased risk for developing osteoporosis, according to a June study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
In the first study testing the effects of TCS on human bone health, scientists sought to uncover evidence relating TCS concentration with bone mineral density (BMD) and osteoporosis. Osteoporosis is a metabolic disease characterized by decreased BMD that heightens risk for fragility fractures. Thirty percent of postmenopausal women in the United States suffer from osteoporosis, with a fragility fracture likelihood of 40%.
Environmental exposure of TCS is found in consumer goods and personal care products, as well as TCS contaminated food or water. TCS is an endocrine-disrupting chemical widely used as an antibacterial, in which 75% of the US population can be detected with urinary TCS concentrations ranging from 7.9 uM to 13.1 uM from 2003-2004. Recently, the FDA banned TCS from over-the-counter hand sanitizer.
Prior laboratory studies conducted on TCS have shown the chemical’s significant impact on interstitial collagen accumulation and an increase in trabecular bone. Women have been found to exhibit higher TCS concentrations than men, but no studies have been conducted to determine the association between TCS with BMD and osteoporosis.
Lead study author Yingjun Li, PhD, from the Hangzhou Medical College School of Public Health in China, highlighted the unknown consequences of TCS exposure in humans amid growing studies of its adverse effects on animals. “Laboratory studies have demonstrated that triclosan may have potential to adversely affect the bone mineral density in cell lines or in animals. However, little is known about the relationship between triclosan and human bone health,” said Li in a statement.
Researchers utilized data derived from a 2005-2010 National Health and Nutrition Examination Survey to examine the association of urinary TCS concentrations with BMD and osteoporosis in 1848 US adult women aged 20 years and older:
The data revealed significant associations between tertile 3 of urinary TCS concentration and lower BMD in regions of total femur (β = -0.016; 95% CI = -0.032, -0.000), intertrochanter (β = -0.022, 95% CI = -0.042,-0.002), and lumbar spine (β = -0.014; 95% CI = -0.029, 0.001) as compared to tertile 1. The negative correlation between TCS urine concentration and BMD unveils diminishing bone health that intensifies through TCS exposure. Compared with women in tertile 1, subjects in tertile 3 were nearly 2.5 times more likely to have osteoporosis prevalence in intertrochanter (odd ratio (OR) = 2.464; 95% CI = 1.190, 5.105). The association was found to be most prominent in postmenopausal women as their odd ratio closely resembled that found in all adult women (OR = 2.250; 95% CI = 1.059, 4.782).
Postmenopausal osteoporosis is the most common type of osteoporosis due to declining levels of estrogen. However, a significant alteration in oxidative balance during the menopausal transition hints at a fundamental issue shown in the study. “As far as we know, this is the first epidemiological study to investigate the association between triclosan exposure with bone mineral density and osteoporosis in a nationally representative sample from US adult women,” said Li. Further studies can distinguish the role that TCS exposure initiates on osteoporosis risk in both premenopausal and postmenopausal women.
Reference
Cai S, Zhu J, Sun L, et al. Association between urinary triclosan with bone mass density and osteoporosis in the US adult women, 2005-2010. [published online June 25, 2019]. Journal of Clinical Endocrinology & Metabolism. doi: 10.1210/jc.2019-00576
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Addressing Maternal Mortality in Medicaid by Focusing on Mental Health
February 15th 2023On this episode of Managed Care Cast, we speak with Inland Empire Health Plan, a managed care plan serving more than 1.4 million residents on Medi-Cal in California, about a new maternal mental health program aimed at supporting new mothers, both before they give birth and afterward.
Listen
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
What We’re Reading: Historic Low of Uninsured; Youth Gender Treatments; Birth Control Recall
August 4th 2023A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.
Read More
Lawyers were questioned in a federal lawsuit intending to overturn approval of a drug used for medication abortion; during the COVID-19 pandemic in 2021, US maternal mortality increased for the third year in a row; the Alzheimer’s Association is lobbying Congress to push for Medicare coverage of new Alzheimer drugs under early access.
Read More